Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Organogenesis Holdings Inc. reported a challenging first quarter in 2026, with net product revenue dropping to $36.3 million, a 58% decrease from the previous year. The company experienced a significant decline in Advanced Wound Care product sales. Despite this, the CEO remains confident about future market share gains and the long-term potential of the company, supported by a comprehensive product portfolio and clinical evidence growth. The operating loss widened to $68.9 million, and the net loss was $53.2 million for the quarter.
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026.